Related Experiment Videos

[Colorectal cancer and inhibition of cyclooxygenase-2]

M Geissler¹, L Mohr, H E Blum

¹Medizinische Klinik II, Universitätsklinik Freiburg, Germany. mgeissl@sun11.ukl.uni-freiburg.de

Deutsche Medizinische Wochenschrift (1946)

|June 8, 2002

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

ESMO open·2024

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial.

ESMO open·2023

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

The B-type natriuretic peptide of the Congo and Timneh grey parrot.

Veterinary research communications·2021

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).

Journal of cancer research and clinical oncology·2020

See all related articles